IMMUCELL CORP /DE/ — Form 8-K
Filed July 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
ImmuCell announced Q2 2026 preliminary sales of $7.2M (11.5% YoY increase) and H1 2026 sales of $17.5M (20.9% YoY increase). Domestic sales grew 27.7% in Q2 to $6.2M, while international sales declined 38.9% to $1.0M. Tri-Shield First Defense sales grew 8.3% to $4.9M; Dual-Force and other products grew 19.1% to $2.3M in Q2.
Why this rating
Growth rates are solid but modest relative to $50.6M market cap. Q2 sales of $7.2M annualize to ~$29M—material but not transformational. International decline offsets strength.
See more from July 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.